FEMPATCH
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FEMPATCH (FEMPATCH).
Estradiol is a steroid hormone that binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways, thereby replacing deficient endogenous estrogen in postmenopausal women.
| Metabolism | Estradiol is primarily metabolized in the liver via oxidation and conjugation; major enzymes include CYP3A4, CYP1A2, and CYP2C9, forming estrone, estriol, and their glucuronide and sulfate conjugates. |
| Excretion | Primarily renal as glucuronide and sulfate conjugates; less than 5% excreted unchanged in urine. Fecal excretion accounts for approximately 5-10% of the dose. |
| Half-life | Terminal elimination half-life is approximately 3-5 hours for estradiol. Transdermal administration results in sustained serum levels with a prolonged effective half-life due to continuous absorption; clinical context: allows once-weekly dosing. |
| Protein binding | Approximately 98% bound to serum albumin and sex hormone-binding globulin (SHBG). |
| Volume of Distribution | Volume of distribution is approximately 1.2 L/kg, indicating extensive distribution into tissues, including estrogen-responsive target organs. |
| Bioavailability | Transdermal bioavailability is approximately 100% as it bypasses first-pass hepatic metabolism; oral estradiol has variable bioavailability (5-20%) due to extensive first-pass metabolism. |
| Onset of Action | Therapeutic estrogenic effects (e.g., relief of vasomotor symptoms) typically occur within 2-4 weeks of continuous transdermal application. |
| Duration of Action | Each patch application provides continuous delivery of estradiol for 7 days. Clinical note: Replace patch weekly to maintain consistent serum levels. |
| Molecular Weight | 272.38 |
Apply one patch transdermally twice weekly (every 3-4 days). Each patch delivers 0.025 mg, 0.0375 mg, 0.05 mg, 0.075 mg, or 0.1 mg estradiol per 24 hours, depending on strength.
| Dosage form | FILM, EXTENDED RELEASE |
| Renal impairment | No specific dose adjustment recommended for GFR; however, use with caution in severe renal impairment due to potential fluid retention. |
| Liver impairment | Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), no specific dose adjustment; monitor liver function. |
| Pediatric use | Not indicated for pediatric use. Safety and efficacy not established. |
| Geriatric use | Initiate at lowest effective dose. Monitor for adverse effects such as thromboembolic events and malignancy. Consider alternative therapies due to increased risk of dementia in women aged 65 years or older. |
| 1st trimester | Contraindicated for use in pregnancy due to risk of fetal harm. Estrogens can cause fetal abnormalities, including congenital heart defects and neural tube defects. |
| 2nd trimester | Contraindicated. Use of estrogens during the second trimester is associated with an increased risk of fetal genital tract abnormalities and other adverse outcomes. |
| 3rd trimester | Contraindicated. Exposure to estrogens in the third trimester may lead to urogenital abnormalities in the fetus and potential long-term effects. |
Clinical note
Comprehensive clinical and safety monograph for FEMPATCH (FEMPATCH).
| Placental transfer | Estrogens, including estradiol, cross the placenta. Transfer is significant, and fetal exposure occurs with maternal administration. |
| Breastfeeding | Estradiol is excreted in human milk. Use during breastfeeding may reduce milk production and quality. Caution is advised; consider alternative treatments if possible. |
■ FDA Black Box Warning
Estrogen therapy increases the risk of endometrial cancer in women with an intact uterus; use with a progestin for endometrial protection is recommended unless hysterectomy has been performed.
| Serious Effects |
Known or suspected pregnancyUndiagnosed abnormal genital bleedingKnown or suspected breast cancerKnown or suspected estrogen-dependent neoplasiaActive or past history of venous thromboembolismActive or past history of arterial thromboembolism (e.g., stroke, MI)Known thrombophilic disorders (e.g., protein C, protein S, or antithrombin deficiency)Hypersensitivity to any component of the patchLiver disease or impaired liver function
| Precautions | Cardiovascular disorders: increased risk of stroke, DVT, and myocardial infarction, Malignant neoplasms: increased risk of endometrial and breast cancer, Dementia: increased risk in women aged 65 years or older, Gallbladder disease, Hypercalcemia in patients with breast cancer and bone metastases, Visual abnormalities (e.g., retinal vascular thrombosis), Elevation of blood pressure, Hypothyroidism: may increase thyroid-binding globulin, requiring dose adjustment of thyroid replacement therapy |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L4 - Possibly Hazardous |
| Teratogenic Risk | Estradiol is contraindicated in pregnancy. First trimester exposure associated with VACTERL anomalies, cardiovascular defects, and hypospadias. Second and third trimester exposure linked to reproductive tract abnormalities in female offspring (e.g., vaginal adenosis, clear cell adenocarcinoma) and potential neurodevelopmental effects. |
| Fetal Monitoring | If inadvertent exposure occurs, monitor fetal anatomy via ultrasound during first trimester. For ongoing use, assess fetal growth and amniotic fluid index periodically. Maternal blood pressure, liver function, and signs of thromboembolism should be monitored. |
| Fertility Effects | Estradiol may disrupt ovulation and endometrial receptivity, potentially impairing fertility. Use as contraception or hormonal therapy can suppress fertility; effects are reversible upon discontinuation. |
| Grapefruit and grapefruit juice may increase estradiol levels by inhibiting CYP3A4; avoid concomitant use. No other significant food interactions known. |
| Clinical Pearls | For transdermal estradiol (Fempatch), apply to clean, dry, hairless skin on lower abdomen or upper quadrant of buttock; rotate sites to minimize skin irritation. Avoid application on or near breasts. Do not apply immediately after bathing or use lotions/sunscreen. The patch releases estradiol continuously, providing stable serum levels. Monitor for signs of thromboembolism and endometrial hyperplasia. |
| Patient Advice | Apply new patch twice weekly (every 3-4 days) as prescribed. · Rotate application sites to lower abdomen or buttock area, avoiding the same spot within 7 days. · Do not expose patch to direct heat sources (heating pads, hot tubs, saunas) as it may increase drug absorption. · If patch falls off, reapply with firm pressure or replace with a new one; do not use tape or adhesives. · Report any signs of blood clots (leg pain, chest pain, shortness of breath) or abnormal vaginal bleeding. · Do not stop or change dose without consulting healthcare provider. |